BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Unresectable Breast Cancer
Interventions: DEVICE: DiviTum® TKa assay|DRUG: CDK4/6 + Endocrine therapy
Sponsor: Washington University School of Medicine
Collaborators: Biovica